Navigation Links
New intranasal influenza vaccine triggers robust immunity with significantly less antigen
Date:10/28/2008

Washington, DC (October 26, 2008) A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation. The new vaccine used only half the standard antigen dose to produce this effect.

Results of the study are being presented today at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.

"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."

In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.

"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."

NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu.


'/>"/>

Contact: Becky Levine
blevine@medthink.com
919-786-4918
MedThink Communications
Source:Eurekalert

Related medicine news :

1. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
2. Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
3. Bioniche Responds to Australian Equine Influenza Outbreak
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. NIH scientists describe ways to better assess benefits of influenza vaccine in the elderly
6. Launch of New Educational Campaign, Spread the Word - NOT the Flu!, Aims to Highlight Importance of Influenza Vaccination
7. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
8. Influenza: Insights into cell specificity of human vs. avian viruses
9. Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates
10. Health Department Reports States First Lab-Confirmed Influenza Case of the Season
11. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... ... January 13, 2017 , ... According to a December 9 ... may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern ... wellness benefits linked to a Mediterranean diet are only some of the many ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... 2017 , ... The Joint Corp. was recently ranked in ... by entrepreneurs and franchisors as a top competitive measurement, the Franchise 500® ranked ... strength and stability, growth rate, and brand power. , “It is always an ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green ... if they can show their work is in the national interest. There are two ... having to be sponsored by an employer; and 2) the submission is made directly ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017  Rosen ... the filing of a class action lawsuit on behalf ... ALXN ) from February 10, 2014 through November ... to recover damages for Alexion investors under the federal ... action, go to http://rosenlegal.com/cases-991.html or call ...
(Date:1/13/2017)... , Jan. 13, 2017 Over the last 10 years ... rapidly (6% – 10% yoy) and are expected to deliver remarkable future ... region, followed by Thailand , the Philippines ... and Singapore .  A member of the G20 and ... almost 40% of the SEA,s economic output and the largest pharma manufacturing ...
(Date:1/13/2017)... -- ... Research and Markets has announced the addition of the ... offering. The disease is divided into two categories ... melanoma, which can be treated with surgery, and advanced melanoma, which ... therapy aiming to prevent disease re-occurrence, and advanced therapies aiming to ...
Breaking Medicine Technology: